Pharmaceutical major Alembic has set a sales target of Rs 25 crore from its newly floated strategic business unit, SynX, in the next 18 months.
At present Alembics products in the cardio and diabetic divisions contribute around Rs 6.5 crore to the turnover of the company.
SynX will comprise cardio and diabetic divisions and plans are afoot to unveil new products through the new business unit, Atul Barman, vice-president (formulations), Alembic, said at a press conference here today.
Also Read
SynX, which has nine products currently, will add seven more in the next few months. Alembic, as part of launching the new business unit, has already cut three existing products, which have contributed marginal revenues, from the list, Barman said.
As part of promoting the products, it will have 121 team members across the country. As part of a promotion strategy, the team members will not offer medicine samples directly to the medical practitioners. Instead, the sample will be provided through doctors request through e-mail and telephone.
For this, Alembic will have a call centre through which medical practitioners can ask for medicine samples.
Doctors can also send the request through a requisition slip provided by the team members.
The setting up of SynX is a result of an extensive research and its observation of the emerging market trends.
The anti-diabetic is a leading therapy segment growing at 30 per cent and the cardiac segment is growing at 11 per cent.